

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-66 cancelled.

(67). (Previously Presented) A compound selected from:

73 N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetyl-amino]propionamide;

X 94 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;~~

X 101 ~~3-(3-Acetyl-amino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;~~

X 158 ~~N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;~~

X 159 ~~N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;~~

1 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

6 N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

4 N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetyl-amino]propionamide;

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

126 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

X 108 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11a5) pyrrolo[2,1-e][1,4]benzodiazepin-10-yl)propionamide;~~

X 96 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;~~

10 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

X 109 ~~N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[c][1,4]diazepin-1-yl)propionamide;~~

X 122 ~~N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;~~

X 123 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;~~

X 115 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;~~

44 N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

79 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

X 129 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-~~  
~~dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;~~

X 121 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-~~  
~~dihydro-benzo[1,4]thiazin-4-yl)butyramide;~~

19 N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-  
2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

20 N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-  
2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

42 N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-  
2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

134 N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-  
[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

135 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-  
oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

9 N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-  
dihydro-[1,5]benzothiazepin-5-yl)butyramide;

28 N-(1(R)-[Bis-(3-aminopropyl)carbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-  
dihydro-[1,5]benzothiazepin-5-yl)butyramide;

72 N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-  
2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

127 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

X 112 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl-propionamide;~~

X 160 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azecin-5-yl)propionamide;~~

X 140 ~~N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;~~

X 155 ~~N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]propionamide;~~

X 144 ~~N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azecin-1-yl)propionylamino]propionamide;~~

15 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

14 N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

58 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

64 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

145 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

68 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

107 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

152 N-[1(R)-(3-Amino-2-hydroxypropylcarbamyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

91 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

8 ✓

X 146 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,11a5)pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;~~

X 147 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;~~

X 141 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;~~

89 N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

138 N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-[3-(4-oxo-7-trifluoromethyl-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

- 143 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;
- 142 N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;
- 137 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
- 136 N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;
- 92 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]-benzothiazepin-5-yl)butyramide;
- X 200 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~
- X 236 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~
- X 205 ~~N-[1(R)-(2-Aminooctylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~
- X 206 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~
- X 242 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;~~

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

- X 130 ~~N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-~~  
~~dibenzo[b,f]azocin-5-yl)pentanamide;~~
- X 241 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-~~  
~~oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;~~
- 216 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-  
dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;
- 244 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-  
oxo-11H-dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;
- 249 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-  
(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;
- 252 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-  
(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;
- 255 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-  
dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;
- X 259 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-~~  
~~chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[c]pyrrolo[1,2-~~  
~~a][1,4]diazepine-10-yl)propionamide;~~
- X 264 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-~~  
~~(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-~~  
~~yl)propionamide;~~

FUNAMIZU et al  
Appl. No. 09/485,845  
September 2, 2003

X 258 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-3-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;~~

165 N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;

253 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

182 N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

X 262 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[c]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;~~

181 N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl) butanamide;

X 263 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[c]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;~~

257 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;

164 N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

FUNAMIZU et al  
 Appl. No. 09/485,845  
 September 2, 2003

254 N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

X 268 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;~~

X 260 ~~N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide; and~~

172 N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

68. (Previously Presented) A composition which comprises an inert carrier and a compound according to claim 85.

69. (Previously Presented) A composition which comprises an inert carrier, a compound according to claim 85 and at least one of the following components:

a growth hormone secretagogues selected from KP-102(GHRP-2), GHRP-6, Hexarelin, and GHRP-1,

a growth hormone releasing factor (GRF) selected from IGF-1, IGF-2 and B-HT920, and  
~~a growth hormone.~~ ✓

70. (Previously Presented) A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to claim 85.